A detailed history of Daiwa Securities Group Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 2,659 shares of SMMT stock, worth $49,643. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,659
Previous 2,659 -0.0%
Holding current value
$49,643
Previous $21,000 176.19%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$2.39 - $10.92 $164 - $753
-69 Reduced 2.53%
2,659 $21,000
Q1 2023

May 02, 2023

BUY
$1.38 - $5.41 $2,646 - $10,376
1,918 Added 236.79%
2,728 $5,000
Q4 2022

Feb 06, 2023

BUY
$0.68 - $5.31 $323 - $2,527
476 Added 142.51%
810 $3,000
Q3 2021

Nov 05, 2021

BUY
$4.83 - $8.27 $864 - $1,480
179 Added 115.48%
334 $2,000
Q4 2020

Feb 04, 2021

BUY
$3.25 - $6.0 $503 - $930
155 New
155 $1,000

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $3.76B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.